Oxford BioDynamics PLC 2023 AR2
The report outlines Oxford BioDynamics' operational and financial performance for the fiscal year ended September 30, 2023. Key highlights include the successful launch of the EpiSwitch PSE Prostate Screening Test in the US and UK, and continued growth in orders for the flagship EpiSwitch CiRT test. Financially, the company reported revenue of £0.5m, up from £0.2m in 2022, alongside an operating loss of £10.2m due to increased investment in staff and infrastructure. The company also established a new US clinical laboratory in Frederick, Maryland, and secured a second FNIH PACT Award to fund immuno-oncology research.
Company: Oxford BioDynamics PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 124
Back to company
Oxford BioDynamics PLC
Annual Report And Accounts
The report outlines Oxford BioDynamics' operational and financial performance for the fiscal year ended September 30, 2023. Key highlights include the successful launch of the EpiSwitch PSE Prostate Screening Test in the US and UK, and continued growth in orders for the flagship EpiSwitch CiRT test. Financially, the company reported revenue of £0.5m, up from £0.2m in 2022, alongside an operating loss of £10.2m due to increased investment in staff and infrastructure. The company also established a new US clinical laboratory in Frederick, Maryland, and secured a second FNIH PACT Award to fund immuno-oncology research.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Oct 1, 2022 - Sep 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees